Literature DB >> 21861209

Imaging of recurrent intramuscular granulomatous masses induced by depot injection of leuprorelin.

Emily N Vinson1, Andresa Braga-Baiak, Leslie G Dodd, Salutario Martinez.   

Abstract

Leuprorelin is a luteinizing hormone-releasing hormone (LH-RH) agonist that is used as an agent of androgen deprivation in some patients with prostate cancer. When administered in depot form, local granulomatous reactions may occur at the injection site, which may mimic masses and which are associated with treatment failure. We present a patient who, over a period of 5 years, developed multiple intramuscular gluteal masses while receiving leuprorelin therapy via intramuscular depot injections; biopsy of one of the masses showed the specific histologic features of leuprorelin granuloma. To our knowledge, this entity has not been described in the radiology literature. Awareness of this entity is necessary to suggest the correct diagnosis in patients with a history of leuprorelin depot injections.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21861209     DOI: 10.1007/s00256-011-1254-8

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  19 in total

1.  Leuprorelin acetate granulomas: recurrent subcutaneous nodules mimicking metastatic deposits at injections sites.

Authors:  M Saxby
Journal:  BJU Int       Date:  2003-01       Impact factor: 5.588

2.  Androgen deprivation therapy for prostate cancer-review of indications in 2010.

Authors:  H Quon; D A Loblaw
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

3.  Granuloma caused by subcutaneous injection of leuprorelin acetate product: case report and histopathological findings.

Authors:  Takeshi Ouchi; Tetushi Koyama; Naho Miyata; Makoto Sugiura
Journal:  J Dermatol       Date:  2006-10       Impact factor: 4.005

4.  Local reactions to luteinizing hormone releasing hormone analog therapy.

Authors:  G Tonini; S Marinoni; V Forleo; M Rustico
Journal:  J Pediatr       Date:  1995-01       Impact factor: 4.406

Review 5.  Leuprorelin acetate granulomas: case reports and review of the literature.

Authors:  K Yasukawa; D Sawamura; H Sugawara; N Kato
Journal:  Br J Dermatol       Date:  2005-05       Impact factor: 9.302

6.  Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?

Authors:  Timothy J Daskivich; William K Oh
Journal:  Urology       Date:  2006-05       Impact factor: 2.649

7.  Treatment of gonadotropin dependent precocious puberty due to hypothalamic hamartoma with gonadotropin releasing hormone agonist depot.

Authors:  V N de Brito; A C Latronico; I J Arnhold; L S Lo; S Domenice; M C Albano; M C Fragoso; B B Mendonca
Journal:  Arch Dis Child       Date:  1999-03       Impact factor: 3.791

8.  Granulomas induced by subcutaneous injection of leuprorelin acetate.

Authors:  Ryoko Sakamoto; Yuko Higashi; Kentaro Mera; Takuro Kanekura; Tamotsu Kanzaki
Journal:  J Dermatol       Date:  2006-01       Impact factor: 4.005

9.  A morphological study of granulomas induced by subcutaneous injection of leuprorelin acetate.

Authors:  T Watanabe; N Yamada; Y Yoshida; O Yamamoto
Journal:  J Cutan Pathol       Date:  2009-12       Impact factor: 1.587

Review 10.  Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer.

Authors:  Rajni Sethi; Nicholas Sanfilippo
Journal:  Clin Interv Aging       Date:  2009-06-09       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.